Seed Amplification Test Expands Access to Neurodegenerative Disease Testing

Amprion, Inc. has secured a multi-million-dollar growth investment from Decathlon Capital Partners to expand its diagnostic testing capacity for neurodegenerative diseases. The San Diego-based company supports diagnosis through seed-amplification testing and highlights SAAmplify-aSYN as the only seed amplification assay available to aid in diagnosing synucleinopathies, including Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with Lewy body co-pathology.

The testing platform employs seed amplification assay (SAA) methodology to deliver pathology-based insights for clinical and research use in neurodegenerative disease. The financing is intended to scale access to this approach for physicians and investigators globally. Amprion is positioned to increase testing throughput as demand continues to rise.

Image Credit: Shutterstock

Amprion’s intellectual property surrounding SAA methodology spans research, drug development, and commercialization, reflecting an ecosystem approach to biomarker-driven neurology. Decathlon Capital Partners provides highly customized growth‑debt financing solutions designed to supply long-term capital without the dilution, loss of control, or added overhead often associated with equity funding.

“Amprion is addressing a critical need in neurological care through its commitment to earlier and more accurate diagnosis of neurodegenerative diseases. We are proud to partner with the company as it scales its innovative testing platform and expands access for physicians and researchers worldwide,” said Matt Hoffman, Managing Director of Decathlon Capital Partners.

"Demand for Amprion's testing is increasing worldwide as researchers and clinicians recognize the value of reliable, pathology-based insights into Parkinson's disease, Lewy body dementia and related neurodegenerative disorders," said Russ Lebovitz, CEO of Amprion. 

"This investment from Decathlon Capital Partners strengthens our ability to meet that demand and accelerate the global adoption of our seed-amplification testing. The tailored financing package provides the operational flexibility needed to support our growth strategy while remaining non-dilutive to existing shareholders and preserving our management control and governance structure," added Lebovitz.

Related Links
Amprion
Decathlon Capital Partners